2099 completed, 509 unknown, 230 terminated, 170 recruiting. 3269 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3269 | Completed 2099, Unknown 509, Terminated 230, Recruiting 170, Withdrawn 116, Not yet recruiting 74, Active not recruiting 53, Enrolling by invitation 14, Suspended 4 |
Follow Metabolic Diseases: new trials by email Literature Review of Metabolic Diseases trials Research Report on Metabolic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Trauma-related Links Between Affective and Metabolic Systems prazosin - Posttraumatic Stress Disorder, Metabolic Syndrome | Phase 4 | Not yet recruiting | VA Office of Research and Development | 70 | 2027-03-01 | 2026-10-15 |
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Sahlgrenska University Hospital | 216 | 2027-01-11 | 2026-08-19 |
| Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes Insulin icodec - Type 2 Diabetes | Phase 4 | Not yet recruiting | Xi'an International Medical Center Hospital | 462 | 2027-01-01 | 2026-08-05 |
| Romosozumab and Denosumab Combination Therapy for Osteoporosis Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2027-01-01 | 2026-11-03 |
| Efficacy of Topical Lidocaine Gel vs. Oral Duloxetine for Painful Diabetic Peripheral Neuropathy Topical Lidocaine 2% Gel, Duloxetine (60 MG) - Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies | Phase 4 | Not yet recruiting | Wah Medical college , POF hospital | 80 | 2026-12-01 | 2026-09-02 |
| Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA iron sulfate - Iron Deficiency Anemia | Phase 4 | Not yet recruiting | Loma Linda University | 100 | 2026-12-01 | 2026-07-10 |
| Pharmacogenetics of Response to Sitagliptin (PRS) Oral Glucose Tolerance Test - Diabetes | Phase 4 | Not yet recruiting | University of Maryland, Baltimore | 400 | 2026-12-01 | 2026-02-18 |
| Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC) The intervention with the MCM is Kidney-Heart GDMT initiation and titration for dose optimization (as clinically tolerated), within 4 months of enrollment in the study. - Chronic Kidney Disease, Type II Diabetes | Phase 4 | Not yet recruiting | Baim Institute for Clinical Research | 570 | 2026-12-01 | 2026-09-10 |
| Sucrosomial Vs Intravenous Iron for Preoperative Anemia Treatment with oral sucrosomial iron, Treatment with intravenous iron - Anemia, Iron Deficiency Anemia | Phase 4 | Withdrawn | University of Rochester | 2026-12-01 | 2026-10-06 | |
| Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes Sotagliflozin, Empagliflozin (oral), Metformin - Type 2 Diabetes Mellitus (DM) | Phase 4 | Not yet recruiting | Allied Hospital Faisalabad | 140 | 2026-12-01 | 2026-11-16 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency Ferric derisomaltose, Placebo (normal saline) - Heart Failure With Preserved Ejection Fraction, Iron Deficiency | Phase 4 | Not yet recruiting | Duke University | 300 | 2026-11-01 | 2026-10-15 |
| Metabolic Surgery for Atrial Fibrillation Elimination Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment - Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Phase 4 | Not yet recruiting | Ali Aminian | 100 | 2026-11-01 | 2026-04-17 |
| Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 178 | 2026-11-01 | 2026-11-05 |
| Iron Repletion in Cystic Fibrosis IV Repletion, PO Repletion - Cystic Fibrosis, Iron Deficiencies | Phase 4 | Not yet recruiting | University of Michigan | 100 | 2026-11-01 | 2026-10-29 |
| Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia inclisiran, SOC - Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 300 | 2026-10-31 | 2026-10-30 |
| Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab) - MAFLD in Prediabetes and Diabetes | Phase 4 | Not yet recruiting | Sherihan AboElyazed Mohamed Khalil | 66 | 2026-10-01 | 2026-10-23 |
| PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses Orforglipron - Diabete Type 2, Pharmacogenomic Drug Interaction | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2026-10-01 | 2026-08-31 |
| PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon) Eroxon®, tadalafil - Type 2 Diabetes, Type 2 Diabetes (T2DM) | Phase 4 | Suspended | University of Miami | 30 | 2026-10-01 | 2026-09-28 |
Showing 20 of 3269. Sign in to see all of them.
Diabetes Mellitus, Type 2 (1186) · Diabetes Mellitus (737) · Insulin Resistance (285) · Diabetes Mellitus, Type 1 (191) · Osteoporosis (166) · Hypertension (165) · Hypercholesterolemia (148) · Obesity (141) · Metabolic Syndrome (139) · Dyslipidemias (130) · Anemia, Iron-Deficiency (102) · Coronary Artery Disease (100) · Cardiovascular Diseases (92) · Hyperglycemia (81) · Renal Insufficiency, Chronic (79)
Nutritional and Metabolic Diseases (3268) · Glucose Metabolism Disorders (2163) · Endocrine System Diseases (1943) · Diabetes Mellitus (1146) · Pathological Conditions, Signs and Symptoms (572) · Cardiovascular Diseases (499) · Vascular Diseases (438) · Lipid Metabolism Disorders (404) · Hyperinsulinism (399) · Urogenital Diseases (340) · Musculoskeletal Diseases (321) · Pathologic Processes (314) · Signs and Symptoms (289) · Bone Diseases (276)
Metformin (294) · Insulin Glargine (216) · Sitagliptin Phosphate (120) · dapagliflozin (117) · Insulin (108) · Pioglitazone (100) · Insulin Aspart (93) · Atorvastatin (91) · empagliflozin (82) · Liraglutide (71) · glimepiride (65) · Exenatide (61) · Ezetimibe (60) · Rosuvastatin Calcium (58) · Insulin Lispro (57)
Sanofi (115) · Novo Nordisk A/S (85) · Novartis Pharmaceuticals (51) · Eli Lilly and Company (50) · AstraZeneca (41) · GlaxoSmithKline (30) · Genzyme, a Sanofi Company (27) · Novartis (26) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (26) · Emory University (25) · Massachusetts General Hospital (23) · Organon and Co (23) · Seoul National University Bundang Hospital (23) · Yonsei University (23) · Seoul National University Hospital (22)
United States (932) · China (273) · South Korea (218) · Germany (154) · Canada (153) · United Kingdom (148) · Italy (143) · Spain (130) · Denmark (118) · Netherlands (103) · France (102) · Japan (89) · Mexico (87) · Brazil (82) · India (77)
PMID 33166419, PMID 32501595, PMID 37435938, PMID 39963952, PMID 34231877, PMID 38018702, PMID 33210751, PMID 34693515, PMID 35224730, PMID 37467180, PMID 37526194, PMID 38682786, PMID 38770818, PMID 40576086, PMID 25765670, PMID 32588430, PMID 32803882, PMID 39641307, PMID 40875095, PMID 11138687, PMID 16018754, PMID 17513708, PMID 19156705, PMID 19366972, PMID 19454394, PMID 20536957, PMID 20923490, PMID 21228246, PMID 21297494, PMID 22002075, PMID 22773702, PMID 22775317, PMID 23435159, PMID 24445038, PMID 30779243, PMID 31865758, PMID 33107592, PMID 33293204, PMID 33813753, PMID 35322793, PMID 35478046, PMID 36088628, PMID 36262060, PMID 37853560, PMID 38189593, PMID 38323855, PMID 38700045, PMID 38979716, PMID 39443013, PMID 39527056
2015 (27), 2014 (14), 2016 (14), 2008 (13), 2019 (12), 2018 (9), 2005 (8), 2025 (7), 2009 (6), 2023 (6), 2017 (5), U54RR014616 (3), R01AR071263 (2), R01DK077166 (2), R01DK107680 (2)